CEO Marc Beer sees "significant room for continued growth as [the company] calibrates activities surrounding the launch of Juxtapid in the U.S."
AEGR says 215 patients are currently using Juxtapid — meeting the full year goal of 250-300 patients on therapy looks like a forgone conclusion.
FY13 Juxtapid sales forecast is lifted to $30-35M from just $15-25M previously. Shares +15% premarket. (PR)
Needham's Chad Messer called it last week.